Page 144 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

142
Chapter 7
References
1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders 2nd edition. Cephalagia. 2004;24(Supplement 1):1-160. http://doi.wiley.com/10.1111/j.1526-4610.2008.01121.x.
2. Olesen J, Bousser M-G, Diener H-C, et al. New Appendix Criteria Open for a Broader Concept of Chronic Migraine. Cephalalgia. 2006;26(6):742-746. doi:10.1111/j.1468-2982.2006.01172.x
3. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808. doi:10.1177/0333102413485658
4. Headache Classification Committee of the International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
5. May A. About the understanding of classifications using SUNCT and SUNA as an example. Neurology. 2019;93(12):523-525. doi:10.1212/WNL.0000000000008121
6. Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. September 2019:033310241987717. doi:10.1177/0333102419877171
7. Deen M, Martinelli D, Pijpers J, et al. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia. 2019;39(8):1058- 1066. doi:10.1177/0333102419847751
8. Goadsby PJ, Holland PR, Martins-oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine – A disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/ physrev.00034.2015
9. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183-187. doi:10.1002/ana.410280213
10. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47(5):614-624. doi:10.1002/1531- 8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N
11. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455-464. doi:10.1038/nrneurol.2016.93
12. Schulte LH, May A. Of generators , networks and migraine attacks. Curr Opin Neurol. 2017;30(3):241- 245. doi:10.1097/WCO.0000000000000441
13. Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010;68(1):81-91. doi:10.1002/ana.21994
14. Louter MA, Bosker JE, van Oosterhout WPJ, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(11):3489-3496. doi:10.1093/brain/awt251
15. Schwedt TJ, Larson-Prior L, Coalson RS, et al. Allodynia and descending pain modulation in migraine: a resting state functional connectivity analysis. Pain Med. 2014;15(1):154-165. doi:10.1111/ pme.12267
16. Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine. Neurology. 2017:10.1212/WNL.0000000000003963. doi:10.1212/WNL.0000000000003963
17. Burstein R, Collins B, Jakubowski M. Defeating Migraine Pain with Triptans: A Race against the Development of Cutaneous Allodynia. Ann Neurol. 2004;55(1):19-26. doi:10.1002/ana.10786
18. Jakubowski M. 2005 Harold G . Wolff Award Winner Terminating Migraine With Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1 / COX2 Inhibitors. herold G. 2005:850-861.
19. Akerman S, Karsan N, Bose P, et al. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain. 2019;142(1):103-119. doi:10.1093/brain/awy313
20. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: Results from the rizatriptan TAME studies. Cephalalgia. 2007;27(9):1055-1060. doi:10.1111/j.1468-2982.2007.01391.x